{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:07:35Z","timestamp":1789376855544,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jaci.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T08:15:39Z","timestamp":1504599339000},"page":"633-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"title":["Therapeutic pipeline for atopic dermatitis: End of the drought?"],"prefix":"10.1016","volume":"140","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.07.006_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2017.07.006_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamadermatol.2014.5432","article-title":"Healthcare utilization, patient costs, and access to care in US\u00a0adults\u00a0with eczema: a population-based study","volume":"151","author":"Silverberg","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jama.2009.136","article-title":"Atopic eczema and attention-deficit\/hyperactivity disorder in a population-based sample of children and adolescents","volume":"301","author":"Schmitt","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2017.07.006_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12888-017-1281-7","article-title":"Allergic diseases in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis","volume":"17","author":"Miyazaki","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jaci.2017.07.006_bib8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjd.14697","article-title":"Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults","volume":"175","author":"Strom","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib9","article-title":"Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with hospitalization or suicide","author":"Thyssen","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.07.006_bib10","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/jid.2015.337","article-title":"Association between atopic dermatitis and depression in US adults","volume":"135","author":"Yu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2014.12.013","article-title":"Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis","volume":"72","author":"Zhang","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjmed.2015.05.041","article-title":"Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis","volume":"128","author":"Hjuler","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.15727","article-title":"Atopic dermatitis and risk of hypertension, type-2 diabetes, myocardial infarction and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project","author":"Drucker","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/all.13085","article-title":"Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis","volume":"72","author":"Egeberg","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.07.006_bib15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jid.2016.11.031","article-title":"Association of atopic dermatitis with cardiovascular risk factors and diseases","volume":"137","author":"Standl","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/all.12957","article-title":"Atopic dermatitis is not independently associated with nonfatal myocardial infarction or stroke among US women","volume":"71","author":"Drucker","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.07.006_bib17","doi-asserted-by":"crossref","first-page":"992e1002","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the national eczema association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pedhc.2006.04.009","article-title":"Atopic dermatitis in Italian\u00a0children: evaluation of its economic impact","volume":"20","author":"Ricci","year":"2006","journal-title":"J Pediatr Health Care"},{"key":"10.1016\/j.jaci.2017.07.006_bib20","first-page":"778","article-title":"Economic burden of atopic manifestations in patients with atopic dermatitis\u2014analysis of administrative claims","volume":"13","author":"Suh","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"suppl","key":"10.1016\/j.jaci.2017.07.006_bib21","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","article-title":"Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines","volume":"139","author":"Eichenfield","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib23","first-page":"203","article-title":"Molecular mechanisms of pruritus","volume":"64","author":"Meng","year":"2016","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","article-title":"Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march","volume":"138","author":"Egawa","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib25","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2014.12.013","article-title":"Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year","volume":"135","author":"Kelleher","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib28","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaci.2015.01.048","article-title":"IL-33 impacts on the skin barrier by downregulating the expression of filaggrin","volume":"135","author":"Seltmann","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl","key":"10.1016\/j.jaci.2017.07.006_bib29","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3476","article-title":"Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths","volume":"13","author":"Gause","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib31","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/jid.2015.285","article-title":"The Janus-faced role of aryl hydrocarbon receptor signaling in the skin: consequences for prevention and treatment of skin disorders","volume":"135","author":"Haarmann-Stemmann","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/exd.12350","article-title":"Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases","volume":"23","author":"Kim","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib33","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"van den Bogaard","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.07.006_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archdermatol.2010.34","article-title":"Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial","volume":"146","author":"Bissonnette","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib36","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jaci.2012.01.063","article-title":"Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling","volume":"129","author":"Nakajima","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Barrier epithelial cells and the control of type 2 Immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2017.07.006_bib38","doi-asserted-by":"crossref","first-page":"e1000067","DOI":"10.1371\/journal.pbio.1000067","article-title":"Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma","volume":"7","author":"Demehri","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jaci.2017.07.006_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.07.006_bib40","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2017.07.006_bib41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2015.08.007","article-title":"Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human TH2 cell subpopulation with enhanced function","volume":"137","author":"Mitson-Salazar","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib42","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jid.2017.02.602","article-title":"Neuronal IL-4Ra and JAK1 signaling medicate chronic itch [abstract]","volume":"137","author":"Oetjen","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib43","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.07.006_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2217\/imt-2016-0023","article-title":"Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies","volume":"8","author":"Zane","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2017.07.006_bib46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib47","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"issue":"suppl\u00a04","key":"10.1016\/j.jaci.2017.07.006_bib48","first-page":"37","article-title":"Efficacy, safety and pharmacodynamics of a high-affinity anti-IgE antibody in patients with moderate to severe atopic dermatitis: a randomized, double-blind, placebo-controlled, proof-of-concept study [abstract]","volume":"25","author":"Bangert","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2340\/00015555-2165","article-title":"Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab","volume":"96","author":"Zink","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.07.006_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","article-title":"Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines","volume":"69","author":"Hotze","year":"2014","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.jaci.2017.07.006_bib51","first-page":"CD007770","article-title":"Oral H1 antihistamines as monotherapy for eczema","author":"Apfelbacher","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2017.07.006_bib52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2006.08.034","article-title":"Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus","volume":"119","author":"Dunford","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib54","first-page":"95","article-title":"A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a potent, oral histamine H-4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults [abstract]","volume":"71","author":"Werfel","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.07.006_bib55","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib56","article-title":"Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients","author":"Nic Dhonncha","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 2 study","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"issue":"suppl","key":"10.1016\/j.jaci.2017.07.006_bib59","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jid.2017.02.329","article-title":"A pathogenic role for Th22\/IL-22 in atopic dermatitis is\u00a0established by a placebo-controlled trial with an anti-IL-22\/ILV-094 mAb [abstract]","volume":"137","author":"Guttman-Yassky","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib60","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib62","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/imm.12528","article-title":"Thymic stromal lymphopoietin-induced interleukin-17A is involved in the development of IgE-mediated atopic dermatitis-like skin lesions in mice","volume":"146","author":"Mizutani","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2017.07.006_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib65","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.02.001","article-title":"New concept of the pathogenesis of atopic dermatitis: interplay\u00a0among the barrier, allergy, and pruritus as a trinity","volume":"70","author":"Kabashima","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.07.006_bib67","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature06029","article-title":"A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord","volume":"448","author":"Sun","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.07.006_bib68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.07.006_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jdermsci.2007.06.003","article-title":"Intraepidermal nerve fibers increase in dry skin of acetone-treated mice","volume":"48","author":"Tominaga","year":"2007","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.07.006_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdermsci.2012.01.007","article-title":"Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC\/Nga mice with atopic dermatitis","volume":"66","author":"Negi","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.07.006_bib71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaci.2012.05.027","article-title":"Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis","volume":"130","author":"Murota","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/ni.3615","article-title":"Linking air pollution to atopic dermatitis","volume":"18","author":"Kabashima","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nm.3912","article-title":"STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch","volume":"21","author":"Shiratori-Hayashi","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib74","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib75","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor a antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.2002.04803.x","article-title":"Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis","volume":"147","author":"Toyoda","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2004.03.047","article-title":"Involvement of substance P in scratching behaviour in an atopic dermatitis model","volume":"491","author":"Ohmura","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaci.2017.07.006_bib78","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jaci.2017.07.006_bib79","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jid.2016.10.008","article-title":"Staphylococcus aureus induces increased serine protease activity in keratinocytes","volume":"137","author":"Williams","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib80","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2017.07.006_bib81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaad.2016.04.066","article-title":"Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis","volume":"75","author":"Gonzalez","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib82","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1172\/JCI70895","article-title":"Topical hypochlorite ameliorates NF-\u03baB-mediated skin diseases in mice","volume":"123","author":"Leung","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.07.006_bib83","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jid.2017.02.312","article-title":"Bleach baths promote early induction of inflammatory pathway genes with no effect on skin bacterial dysbiosis in AD subjects [abstract]","volume":"137","author":"Knowlden","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.006_bib84","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2133.2008.08836.x","article-title":"Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study","volume":"159","author":"Gueniche","year":"2008","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaci.2017.07.006_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86955","article-title":"Transplantation of human skin microbiota in models of atopic dermatitis","volume":"1","author":"Myles","year":"2016","journal-title":"JCI Insight"},{"issue":"378","key":"10.1016\/j.jaci.2017.07.006_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis","volume":"9","author":"Nakatsuji","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.07.006_bib87","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jaci.2015.12.1312","article-title":"Skin barrier impairment at birth predicts food allergy at 2 years of age","volume":"137","author":"Kelleher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib88","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaci.2014.08.005","article-title":"Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention","volume":"134","author":"Simpson","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaci.2014.07.060","article-title":"Application of moisturizer to neonates prevents development of atopic dermatitis","volume":"134","author":"Horimukai","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib90","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaci.2016.07.029","article-title":"Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year","volume":"139","author":"Kennedy","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib91","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early\u00a0pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2\/TH1 cell imbalance, whereas adults acquire CLA(+) TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.006_bib92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917311995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917311995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:05:16Z","timestamp":1758791116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917311995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0091674917311995"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.07.006","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic pipeline for atopic dermatitis: End of the drought?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}